Bachem vs Nitto Denko Avecia: CDMO Comparison
Side-by-side comparison of Bachem and Nitto Denko Avecia on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
On a 13-modality CDMO landscape, both Bachem and Nitto Denko Avecia qualify as Oligo/ASO manufacturers; Bachem carries the higher composite Signal Score for Oligo/ASO programs in this comparison.
What to evaluate for Oligo/ASO programs
Both Bachem and Nitto Denko Avecia qualify as Oligo/ASO CDMOs. When choosing between them for Oligo/ASO programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Synthesis scale
Match synthesizer scale (mmol to mol) to your clinical and commercial demand, and confirm the CDMO can scale without shifting the impurity profile.
Chemistry & conjugation
Confirm experience with your backbone and modifications (phosphorothioate, 2'-MOE/F) and any conjugation (GalNAc, lipid) your molecule requires.
Purity & analytics
Full-length product, deletion/addition impurities, and residual metals drive release. Look for established orthogonal analytics.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
Frequently asked: Bachem vs Nitto Denko Avecia
Which has the stronger FDA inspection record, Bachem or Nitto Denko Avecia?
Both Bachem and Nitto Denko Avecia maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Bachem has 1 FDA inspection on record; Nitto Denko Avecia has 2.
Which is better for Oligo/ASO manufacturing — Bachem or Nitto Denko Avecia?
Both Bachem and Nitto Denko Avecia are tagged as Oligo/ASO CDMOs in our directory, so both are credible options for Oligo/ASO programs. The most important differentiator for Oligo/ASO selection is typically synthesis scale: Match synthesizer scale (mmol to mol) to your clinical and commercial demand, and confirm the CDMO can scale without shifting the impurity profile. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Bachem carries a Signal Score of 84/100 and Nitto Denko Avecia carries 80/100 — essentially tied for Bachem. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →